Epithelial cells require correct polarity for their function. Their polarity and patterning is established during organogenesis. Epithelial cells are often polarized in two axes, in the apical-basolateral axis and in the plane of the epithelium, called planar cell polarization or PCP. Typical PCP examples include features of mammalian skin or internal organs, e.g. the inner ear epithelium with its sensory cilia, and insect cuticular structures in invertebrates. The establishment of PCP in Drosophila serves as a paradigm to study PCP determination and the coordination of polarized cell shape changes in general. PCP is coordinated by long range signals, resulting in the activation of the Frizzled (Fz) receptor- and its associated signaling cascade (Fz/PCP signaling). The Fz/PCP pathway is conserved throughout evolution and also regulates several other aspects of coordinated cellular polarization, including directed cell migration during mammalian gastrulation. Strikingly, Fz/PCP ^signaling is distinct from the canonical Wnt/Fz-^Catenin pathway. The regulation of signaling specificity ^between these two pathways activated by the same receptors is only poorly understood, but critical for development and disease. Moreover, the link between Fz/PCP signaling and the resulting cellular responses, including cytoskeletal reorganization and specific transcriptional events are not yet understood. The scope of this application is to investigate the specific roles of newly identified genes required for PCP determination and cell shape change coordination. Their function in Fz/PCP signaling and/or in cellular polarization events will be investigated genetically and biochemically. A combination of in vivo studies in Drosophila, cell culture analyses and biochemical experiments will be utilized to achieve these goals. The processes of PCP establishment and Wnt/Fz signaling have been linked to several medical abnormalities (including deafness in the case of the inner ear epithelium) and cancer (several components of the pathway are proto-oncogenes or tumor suppressors). Thus the information acquired in this application will both advance our understanding of cellular polarization and patterning, and will be of medical relevance, particularly for the study of carcinogenesis.

Public Health Relevance

The goal of this project is to develop a blood test that can predict whether an individual patient?s ovarian cancer will be adequately surgically resectable or not. The test would benefit all women presenting with advanced stage ovarian cancer, as those with resectable cancer could proceed to surgery with the knowledge that their disease can be adequately removed, and patients with poorly resectable cancer could avoid ineffective surgery and instead undergo prompt treatment with neoadjuvant chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-13
Application #
8322537
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
13
Fiscal Year
2011
Total Cost
$200,810
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications